<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The biological behavior of VEGF-B, a ligand of the receptor VEGFR-1, is still enigmatic </plain></SENT>
<SENT sid="1" pm="."><plain>Despite its high sequence homology to the better known angiogenetic factor VEGF-A, the function of VEGF-B has remained elusive </plain></SENT>
<SENT sid="2" pm="."><plain>Especially, its role in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biology has thus far not been defined </plain></SENT>
<SENT sid="3" pm="."><plain>In the present study we address the question of whether VEGF-B could play a role in the metastatic process of colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>Using immunohistochemistry we investigated its expression in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue of 91 non-metastatic, lymphogenous-metastatic and haematogenous-metastastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Independently of metastatic status, VEGF-B was expressed in endothelial as well as in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="6" pm="."><plain>81% of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> showed a positive, partly focal, partly disseminated endothelial expression in intratumoral vessels and the vascular fraction throughout the invasive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> margin </plain></SENT>
<SENT sid="7" pm="."><plain>Almost <z:hpo ids='HP_0000001'>all</z:hpo> of the VEGF-B positive vessels were of blood vascular origin </plain></SENT>
<SENT sid="8" pm="."><plain>Many of these were thick-walled blood vessels with atherosclerotic changes characterizing preexistent but not angiogenetic vasculature </plain></SENT>
<SENT sid="9" pm="."><plain>Thus it appears that VEGF-B might be an important ligand to ensure the blood supply for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> survival </plain></SENT>
<SENT sid="10" pm="."><plain>46% of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> presented an additional tumoral VEGF-B expression which significantly correlated with haematogenous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (p=0.006) </plain></SENT>
<SENT sid="11" pm="."><plain>These morphological results provide evidence for a probable pathobiological significance of VEGF-B in the <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, especially in the case of haematogenous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>It appears that VEGF-B might be an important ligand in the signalling between the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and preexisting blood vessels to ensure a functional blood supply for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> survival </plain></SENT>
</text></document>